BioCardia’s Morph DNA Deflectable Guide Catheter Cleared by FDA


January 14, 2020—BioCardia, Inc. announced FDA 510(k) clearance for the Morph DNA deflectable guide catheter used to guide the Helix biotherapeutic delivery system during CardiAMP cell therapy delivery in the heart.

According to BioCardia, the Morph DNA is designed to enhance procedural control of therapeutic catheters, such as the Helix system, during delivery of cell therapy. It is intended to provide ease of use through bidirectional deflection, reduced torque build-up or whip, enhanced fluoroscopic visibility, and improved ergonomics.

The company noted that helically arranged pullwires in the device, resembling the double helix of a DNA strand, increase catheter stability, rendering it virtually whipless around curves and within the heart. The device also features a new handle design with an adjustable brake for finer catheter control during procedures.

Gerald Koenig, MD, commented in BioCardia’s press release, “The Morph DNA deflectable guide enables navigation within the cardiac chambers without building up torque. This is hugely beneficial for controlling the delivery of therapeutic catheters, such as Helix. The ergonomic features simplify the handling and can reduce procedural delays.” Dr. Koenig is a cardiologist and Principal Investigator of the CardiAMP Heart Failure Trial at Henry Ford Health System in Detroit, Michigan.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.